InVivo Therapeutics to Present at Sidoti's Semi-Annual New York Micro-Cap Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced thatFrank Reynolds, InVivos Chief Executive Officer, is scheduled to make a presentation at theSidoti Semi-Annual New York Micro-Cap Conferenceat 8:00-8:35 AM EDT on Thursday, June 14, 2012, in the Estate 4 Carnegie Hall room. The Company's executives will also meet with financial community members to discussthe Company's ongoing operations. The conference will be held at the Grand Hyatt New York Hotel in midtown Manhattan.

About Sidoti & Company, LLC

Sidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard for independent small-cap equity research, while rapidly becoming a driving force in micro-cap research, launching coverage of more than 100 equities of $200 million market cap or less since inception in mid-2010. Its analysts mine dozens of industries to provide unbiased, institutional-quality research focusing on the investment merits of profitable companies at a sub-$3 billion market cap, and it anticipates extending coverage to 700 small-cap equities by the end of 2012.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Companys ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companys products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

View post:
InVivo Therapeutics to Present at Sidoti's Semi-Annual New York Micro-Cap Conference